NCT03687931
Completed
Phase 1
A Phase 1/2 Dose-Ranging, Open-Label, Randomized, Clinical Study to Assess the Efficacy and Safety of Dexamethasone Ophthalmic Suspension Eye Drops for the Treatment of Inflammation Associated With Cataract Surgery
Overview
- Phase
- Phase 1
- Intervention
- Dexamethasone
- Conditions
- Inflammation Eye
- Sponsor
- iDrop, Inc.
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Anterior Chamber Cell
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
Patients at least 40 years of age who are undergoing cataract surgery will be randomized to receive treatment with one of two dose levels of dexamethasone ophthalmic suspension eye drops to determine if the drops decrease inflammation inside the eye and are safe after cataract surgery.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male or female patients at least 40 years of age scheduled for unilateral cataract surgery by phacoemulsification with posterior chamber intraocular lens implantation.
Exclusion Criteria
- •Patients who have received a periocular corticosteroid injection in the study eye in the 3 months prior to screening.
- •Patients who anticipate requiring treatment with any corticosteroids by any route, except inhalation, during the study.
- •Patients who are known steroid responders
Arms & Interventions
Arm 1
Dexamethasone suspension dose level 1
Intervention: Dexamethasone
Arm 2
Dexamethasone suspension dose level 2
Intervention: Dexamethasone
Outcomes
Primary Outcomes
Anterior Chamber Cell
Time Frame: 30 days
Number of cells in the anterior chamber
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 2
A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patients with Pyruvate Kinase DeficiencyNL-OMON47068Agios Pharmaceuticals, Inc.15
Active, not recruiting
Phase 1
A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patients with Pyruvate Kinase DeficiencyPyruvate Kinase DeficiencyMedDRA version: 21.1Level: PTClassification code 10037682Term: Pyruvate kinase deficiency anaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2015-000484-13-GBAgios Pharmaceuticals Inc75
Active, not recruiting
Phase 1
A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patients with Pyruvate Kinase DeficiencyPyruvate Kinase DeficiencyMedDRA version: 18.0Level: PTClassification code 10037682Term: Pyruvate kinase deficiency anaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2015-000484-13-FRAgios Pharmaceuticals Inc75
Active, not recruiting
Phase 1
A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patientswith Pyruvate Kinase DeficiencyPyruvate Kinase DeficiencyMedDRA version: 21.1Level: PTClassification code 10037682Term: Pyruvate kinase deficiency anaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2015-000484-13-ITAGIOS PHARMACEUTICALS, INC.75
Active, not recruiting
Phase 1
A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patients with Pyruvate Kinase DeficiencyPyruvate Kinase DeficiencyMedDRA version: 18.0Level: PTClassification code 10037682Term: Pyruvate kinase deficiency anaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2015-000484-13-NLAgios Pharmaceuticals Inc75